MA30530B1 - Synthese de peptides insulinotropes - Google Patents

Synthese de peptides insulinotropes

Info

Publication number
MA30530B1
MA30530B1 MA31510A MA31510A MA30530B1 MA 30530 B1 MA30530 B1 MA 30530B1 MA 31510 A MA31510 A MA 31510A MA 31510 A MA31510 A MA 31510A MA 30530 B1 MA30530 B1 MA 30530B1
Authority
MA
Morocco
Prior art keywords
fragments
solution
synthesis
insulinotropic peptides
solid phase
Prior art date
Application number
MA31510A
Other languages
English (en)
Inventor
Lin Chen
Yeun-Kwei Han
Christopher R Roberts
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30530B1 publication Critical patent/MA30530B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Synthèse de peptides insulinotropes La présente invention concerne la préparation de peptides insulinotropes qui sont synthétisés en utilisant une approche en phase solide et en solution (« hybride »). De manière générale, l'approche comprend la synthèse de trois fragments peptidiques intermédiaires différents en utilisant un processus chimique en phase solide. Un processus chimique en solution est ensuite utilisé pour ajouter des aminoacides supplémentaires à un des fragments. Puis les fragments sont couplés les uns aux autres dans la phase solide-solution. L'utilisation d'une pseudoproline dans un des fragments facilite la synthèse en phase solide de ce fragment et facilite également le couplage ultérieur, en solution, de ce fragment aux autres fragments. La présente invention est très utile pour former des peptides insulinotropes tels que le GLP-1(7-36) et ses analogues naturels et non naturels.
MA31510A 2006-06-23 2008-12-25 Synthese de peptides insulinotropes MA30530B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81591906P 2006-06-23 2006-06-23

Publications (1)

Publication Number Publication Date
MA30530B1 true MA30530B1 (fr) 2009-06-01

Family

ID=38596729

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31510A MA30530B1 (fr) 2006-06-23 2008-12-25 Synthese de peptides insulinotropes

Country Status (33)

Country Link
US (2) US20080004429A1 (fr)
EP (1) EP2035451B1 (fr)
JP (1) JP4537495B2 (fr)
KR (1) KR101087859B1 (fr)
CN (1) CN101563364B (fr)
AR (1) AR061604A1 (fr)
AT (1) ATE466881T1 (fr)
AU (1) AU2007263043B2 (fr)
BR (1) BRPI0713575A2 (fr)
CA (1) CA2654610C (fr)
CL (1) CL2007001835A1 (fr)
CR (1) CR10463A (fr)
CY (1) CY1110186T1 (fr)
DE (1) DE602007006310D1 (fr)
DK (1) DK2035451T3 (fr)
EC (1) ECSP088999A (fr)
ES (1) ES2341588T3 (fr)
HR (1) HRP20100302T1 (fr)
IL (1) IL195421A0 (fr)
MA (1) MA30530B1 (fr)
MX (1) MX2008015935A (fr)
MY (1) MY144608A (fr)
NO (1) NO20084863L (fr)
NZ (1) NZ573093A (fr)
PL (1) PL2035451T3 (fr)
PT (1) PT2035451E (fr)
RS (1) RS51281B (fr)
RU (1) RU2448978C2 (fr)
SI (1) SI2035451T1 (fr)
TW (1) TWI331155B (fr)
UA (1) UA96602C2 (fr)
WO (1) WO2007147816A1 (fr)
ZA (1) ZA200810072B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
EP2222695A2 (fr) * 2007-12-11 2010-09-01 F. Hoffmann-La Roche AG Synthèse de peptides insulinotropiques mettant en uvre des techniques de combinaison de phases solides et en solution
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
CN102414220A (zh) * 2009-05-01 2012-04-11 霍夫曼-拉罗奇有限公司 使用固相和液相组合技术的促胰岛素肽合成
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
US20120157382A1 (en) 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
DK2788110T3 (en) * 2011-12-08 2019-02-11 Pentair Water Pool & Spa Inc AQUACULTURE SYSTEM AND PROCEDURE TO OPERATE A PUMP IN SUCH A SYSTEM
RU2643515C2 (ru) 2011-12-29 2018-02-02 Ново Нордиск А/С Дипептид, содержащий непротеиногенную аминокислоту
CN104936610A (zh) 2012-11-13 2015-09-23 益普生制药股份有限公司 Glp-1类似物的纯化方法
WO2014077801A1 (fr) 2012-11-13 2014-05-22 Ipsen Pharma S.A.S. Procédé de purification pour préparer du tasoglutide de haute pureté
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
CA3093221A1 (fr) 2018-03-09 2019-09-12 Enzypep B.V. Synthese chimio-enzymatique de liraglutide, de semaglutide et de glp-1
EP3762408A1 (fr) 2018-03-09 2021-01-13 Enzypep B.V. Synthèse chimio-enzymatique de semaglutide, de liraglutide et de glp-1
ES2938734T3 (es) * 2018-10-09 2023-04-14 Fresenius Kabi Ipsum S R L Procedimiento para la fabricación de análogos de GLP-1
TWI738260B (zh) 2019-03-25 2021-09-01 台灣神隆股份有限公司 純化利拉魯肽之方法
CN114401981A (zh) * 2019-06-18 2022-04-26 北京费森尤斯卡比医药有限公司 胰高血糖素制造方法
EP3753946A1 (fr) 2019-06-18 2020-12-23 Fresenius Kabi iPSUM S.r.l. Procédé amélioré pour la préparation de glucagon à pureté élevée
US20230406900A1 (en) * 2022-06-01 2023-12-21 Scinopharm Taiwan, Ltd. Process for preparing glucagon-like peptide-1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0820296A4 (fr) * 1995-04-14 1999-06-30 Univ Tulane Analogues du facteur liberant l'hormone de croissance
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6903186B1 (en) * 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005063792A2 (fr) * 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Procedes pour recuperer un peptide clive a partir d'un support

Also Published As

Publication number Publication date
CN101563364A (zh) 2009-10-21
WO2007147816A1 (fr) 2007-12-27
JP4537495B2 (ja) 2010-09-01
TW200811195A (en) 2008-03-01
KR101087859B1 (ko) 2011-11-30
CL2007001835A1 (es) 2008-03-14
EP2035451B1 (fr) 2010-05-05
US20110213082A1 (en) 2011-09-01
RS51281B (sr) 2010-12-31
PT2035451E (pt) 2010-06-09
AU2007263043A1 (en) 2007-12-27
JP2009541257A (ja) 2009-11-26
RU2448978C2 (ru) 2012-04-27
ATE466881T1 (de) 2010-05-15
EP2035451A1 (fr) 2009-03-18
UA96602C2 (ru) 2011-11-25
ES2341588T3 (es) 2010-06-22
DK2035451T3 (da) 2010-06-07
TWI331155B (en) 2010-10-01
IL195421A0 (en) 2011-08-01
BRPI0713575A2 (pt) 2013-02-13
ZA200810072B (en) 2009-12-30
AU2007263043B2 (en) 2012-11-29
NZ573093A (en) 2012-01-12
CY1110186T1 (el) 2015-01-14
CA2654610A1 (fr) 2007-12-27
DE602007006310D1 (fr) 2010-06-17
CA2654610C (fr) 2012-03-20
AR061604A1 (es) 2008-09-10
NO20084863L (no) 2009-01-22
SI2035451T1 (sl) 2010-06-30
US20080004429A1 (en) 2008-01-03
ECSP088999A (es) 2009-01-30
MY144608A (en) 2011-10-14
RU2009101969A (ru) 2010-07-27
CR10463A (es) 2009-02-26
PL2035451T3 (pl) 2010-08-31
CN101563364B (zh) 2014-04-02
HRP20100302T1 (hr) 2010-06-30
MX2008015935A (es) 2009-01-13
KR20090023619A (ko) 2009-03-05

Similar Documents

Publication Publication Date Title
MA30530B1 (fr) Synthese de peptides insulinotropes
González-Montoya et al. Bioactive peptides from germinated soybean with anti-diabetic potential by inhibition of dipeptidyl peptidase-IV, α-amylase, and α-glucosidase enzymes
TWI646112B (zh) Ｐｄ－１／ｐｄ－ｌ１及ｃｄ８０（ｂ７－１）／ｐｄ－ｌ１蛋白質／蛋白質交互作用之大環狀抑制劑
TWI255271B (en) Analogues of GLP-1
Ferder et al. The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system
JP5635529B2 (ja) グルカゴン類似体
MX2010006044A (es) Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion.
Thapa et al. The emergence of cyclic peptides: The potential of bioengineered peptide drugs
WO2005076744A3 (fr) Procede de preparation de conjugues peptides/oligonucleotides
JP2016147895A (ja) 自己免疫疾患の治療方法及びそれに関する試薬
JP2010001301A (ja) Ｇｌｐ−１の類似体
SA518391996B1 (ar) نظائر عامل النمو الجلدي شبيه مجال أ ببدائل حمض دهني
Dekan et al. Total synthesis of human hepcidin through regioselective disulfide‐bond formation by using the safety‐catch cysteine protecting group 4, 4′‐dimethylsulfinylbenzhydryl
WO2010059920A3 (fr) Système et procédé pour générer une image en 2d à partir d'un ensemble de données de tomosynthèse
US9364449B2 (en) Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
Thomas et al. Proline editing: a divergent strategy for the synthesis of conformationally diverse peptides
Lagu et al. Selective PPARδ modulators improve mitochondrial function: potential treatment for duchenne muscular dystrophy (DMD)
MA31133B1 (fr) Nouveau peptide d'actinomadura namibiensis
Tornøe et al. Divergent protein synthesis of Bowman–Birk protease inhibitors, their hydrodynamic behavior and co-crystallization with α-chymotrypsin
Bojarska et al. A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0: A Case Study of ACEI
EA201171292A1 (ru) Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth)
Majer et al. Structure‐based subsite specificity mapping of human cathepsin D using statine‐based inhibitors
Gary et al. Peptide Carbo cycles: From− SS–to− CC–via a Late-Stage “Snip-and-Stitch”
JP6517732B2 (ja) Ｄｐｐ−４阻害剤、血糖値上昇抑制剤およびｄｐｐ−４阻害用食品
Rodhi et al. A review on the types of amino acid at ultimate, penultimate and antepenultimate position in some dipeptidyl-peptidase IV inhibitory peptides based on molecular docking analysis